Ferd Lewis: University of Hawaii must start faster against upcoming unbeaten foes

Mahalo for supporting Honolulu Star-Advertiser. Enjoy this free story!

Read more

Overtime, Opendorse Launch Program For College Athletes, Schools For Upcoming Name, Image, Likeness Changes

In January, the NCAA is expected to approve changes that will allow Division I athletes to make money off their name, image and likeness (NIL for short) after decades of pushback and punishment where making any kind of revenue while an amateur was college sports’ cardinal sin.

Student-athletes will, as soon as next fall, be able to give paid private lessons, operate clinics, charge for autographs, profit from endorsements, enter deals with agents and crowdfund as long as the college’s name or logo is not mentioned, according to a thorough National Law Review article published last week.

This is going to impact tens of thousands of college-aged kids right away and so many more in the future. For those athletes and schools who may need guidance, youth-focused sports brand Overtime has teamed up with Opendorse— an athlete marketing platform already used by the NHL, Clemson University, the PGA Tour, Pittsburgh Steelers superstar wide receiver Juju Smith-Schuster and more than 25,000 organizations, schools, teams, players and sponsors— to help prepare for these changes.

Founded in 2012 by two former University of Nebraska football players, Opendorse will use its eight years of experience to provide the resources and social media and marketing tools to help athletes and schools best navigate these unprecedented, long-awaited upcoming changes. Partnering with a company like Overtime, which has a huge reach among high school and college-aged kids, with its viral social and video content geared towards the athletes and their followers, made perfect sense.

The combined effort is called Opendorse Ready, which athletes, schools and teams can apply for, but the service would remain free for college students. Clients would be able to access different marketing tools at various price points and have the option to select an Overtime package. That package includes includes what the companies call athlete-centric content creation with a variety of Overtime created media-capture options like video which could be customized into videos and highlights both for players and teams, interviews and even episodes for a potential athlete or team-focused video series. That content would then be converted using Opendorse’s marketing tools to publish to their personal social media channels.

“This partnership is a natural evolution for both companies as we enter the NIL era,” said Blake Lawrence, Opendorse’s co-founder and CEO. “When student-athletes can bring Overtime-created content to their fans and followers, they will be in a position to build engaged audiences that will soon attract sponsors in the same way media companies like Overtime do today. Our partnership makes it a reality for athletes across the country to maximize, and eventually manage, this endorsement value while helping to position college athletics programs for the future.”

Read more

Ascendis Pharma A/S Announces Presentations for its Endocrinology Rare Disease Clinical Programs at Upcoming Medical Conferences

COPENHAGEN, Denmark, Oct. 21, 2020 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced five presentations featuring the company’s endocrinology rare disease programs at two upcoming medical conferences: European Calcified Tissue Society (ECTS) 2020, taking place online October 22–24, 2020, and the Pediatric Endocrinology Nursing Society (PENS) national conference, taking place online November 2–5, 2020.

During ECTS, results from the phase 2 PaTH Forward Trial of TransCon PTH in adult hypoparathyroidism (HP) will be presented. During PENS, data from the phase 3 fliGHt Trial of TransCon hGH (lonapegsomatropin) in pediatric growth hormone deficiency (GHD) and from two clinical trials of the auto-injector for lonapegsomatropin. Additionally, the company will present posters highlighting the impact of achondroplasia (ACH) on the quality of life in children and their parents, which will help inform the TransCon CNP program.

“Ascendis Pharma is committed to supporting the endocrinology community, and we are excited to present data across all three of our endocrinology rare disease programs,” said Aimee Shu, M.D., Senior Medical Director, Clinical Development at Ascendis Pharma. “The data being presented at this year’s ECTS and PENS meetings highlight our portfolio of investigational product candidates and demonstrate important clinical and quality of life outcomes for patients and caregivers, including our first presentation of clinical data on our proprietary auto-injector for lonapegsomatropin.”

Presentation Details

ECTS

Poster Presentation

Title

 

Date/Time

 

Design and Topline Results of TransCon PTH, a Long-acting Parathyroid Hormone (PTH), Phase 2 Trial in Patients with Hypoparathyroidism

 

Presented on Saturday, October 24, 2020 at 4:55–5:00 p.m. (CST) with live Q&A to follow.

 

PENS 2020

Poster Presentations

Title

 

Date/Time

 

Introduction of a Novel GH Auto-Injector for Once-weekly Administration of TransCon hGH (lonapegsomatropin)

 

Posters are available during PENS with live Q&A on Thursday, November 5, 2020 from 2:15–2:45 p.m. (ET).

 

Treatment Experience of Children with Growth Hormone Deficiency in the Phase 3 fliGHt Trial: Switching from Daily Growth Hormone to Once-weekly TransCon hGH (lonapegsomatropin)

 

 

Pediatric Achondroplasia: Impacts on Children’s Functioning and Well-being

 

 

Experiences of Parents of Children with Achondroplasia: Impacts on Quality of Life

 

 

The posters will be available on the Ascendis website under Selected Publications in the Pipeline section: https://ascendispharma.com/product-pipeline/publications/.   If you are a healthcare provider who would like more information, please contact: [email protected]

About TransCon™ Technology Platform

TransCon refers to “transient conjugation.” The proprietary TransCon platform is an innovative technology to create new therapies that are designed to potentially optimize therapeutic effect, including efficacy, safety and dosing frequency. TransCon molecules have three components: an unmodified parent drug, an inert carrier that protects it, and a linker that temporarily binds the two. When bound, the carrier inactivates and shields the parent drug from clearance. When injected into the body, physiologic conditions (e.g., pH and temperature) initiate the release of the active, unmodified parent drug in a predictable manner. Because the parent drug is unmodified, its original mode of action is expected to be maintained. TransCon technologies can be

Read more